

Indian Journal of Novel Drug Delivery

An Official Publication of Karnataka Education and Scientific Society

Research Article

Formulation and Evaluation of Amlodipine Transdermal Patches using Hydroxypropylmethylcellulose

LINCY JOHN *, ARUN KUMAR, SANDRA SAMUEL

Department of Pharmaceutics, KMCH College of Pharmacy. DR MGR University, Coimbatore-641048, Tamilnadu

Article history: Received on 03 August 2013 Modified on 10 September 2013 Accepted on 15 September 2013

Keywords: Transdermal, hydroxypropylmethylcellulose, Amlodipine. The aim of our study was to design and evaluate Amlodipine transdermal patches using polymers such as hydroxypropylmethylcellulose. Matrix type transdermal patches containing Amlodipine were prepared by solvent casting method by using polymer like hydroxypropylmethylcellulose (1%, 1.5%, 2% and 2.5%) and a total of eight formulations were prepared. Plasticizers used were propylene glycol and dibutylpthalate. The transdermal patches were evaluated for their physicochemical properties like folding endurance, thickness, percentage moisture loss, percentage moisture absorption, drug content and water vapour transmission The diffusion studies were performed by using franz diffusion cell. rate. Formulation H7 (2% hydroxypropylmethylcellulose with Dibutylphthlate) as plasticizers showed a maximum release of 99% in 24 hours. Out of these eight formulation of hydroxypropylmethylcellulose, 2% hydroxypropylmethylcellulose (H7) was optimized since they produced a sustained and a complete release over a period of 24 hours. Thus the knowledge on the use of chitosan to control drug release in transdermal delivery systems might be applicable to other transdermal drug delivery system as well.

© KESS All rights reserved

INTRODUCTION

Delivering medicine to the general circulation through the skin is seen as a desirable alternative to taking it by mouth or by oral route. Patients often forget to take their medicine and also they get tired of swallowing pills. Additionally bypassing the gastrointestinal tract would obviate the GI irritation that frequently occurs & avoid partial first pass inactivation by the liver. Further, steady absorption of drug over hours or days is usually preferable to blood level spikes and troughs produced by oral dosage forms^[1].

These advantages are offered by the currently marketed transdermal products. Transdermal drug delivery is defined as self-contained, discrete dosage forms which when applied to intact skin deliver the drug through the skin at controlled rate to the systemic circulation. The transdermal patches uses a polymer membrane to control the rate at which the drug contained in the reservoir within the patch can pass through the skin and into the blood stream ^[2].

Today most of the drug are taken orally but, they are found not to be as effective as desired, so to improve such character TDDS was emerged. Drug delivery through the skin to achieve a systemic effect of a drug is commonly known as transdermal drug delivery system. These are dosage forms which involves drug transport to viable epidermal and or dermal tissue of the skin for local therapeutic effect while a very major fraction of the drug is transported into systemic blood circulation. Currently TDDS is one of the most promising methods for drug application. Transdermal drug delivery provides a leading edge over injectables and oral route by increasing patient compliances and avoiding first pass metabolism respectively. TDDS not only provides a controlled, constant administration of drug, but also allows continuous input of drug with short biological half life and eliminates pulsed entry into systemic circulation which often causes undesirable side effect^[2].

Over the last two decades more than 35 transdermal patches have been approved, generating sales of \$3.2 billion in 2002 to \$4.5 billion in 2008. More recently such dosage forms have been developed and or modified in order to

^{*}Author for Correspondence: Email: lincy.bikaner@gmail.com

enhance the driving force of diffusion (thermodynamic activity) and or increase the permeability of skin. These approaches include permeability enhancer, prodrug, liposome and other vesicles ^[3].

Transdermal drug delivery provides a leading edge over injectables and oral route by increasing patient compliances and avoiding first pass metabolism respectively. TDDS not only provides a controlled, constant administration of drug, but also allows continuous input of drug with short biological half life and eliminates pulsed entry into systemic circulation which often causes undesirable side effect ^[4,5].

Applications of Transdermal Patches

- The highest selling transdermal patch in the United States is the nicotine patch, which releases nicotine in controlled doses to help with cessation of tobacco smoking.
- Two opioid medications used to provide round-the-clock relief for severe pain are often prescribed in patch form: Fentanyl (marketed as Duragesic) and Buprenorphine (marketed as BuTrans).
- Estrogen patches are sometimes prescribed to treat menopausal symptoms as well as post-menopausal osteoporosis. Other transdermal patches for hormone delivery include the contraceptive patch (marketed as Ortho Evra or Evra).
- Nitroglycerin patches are sometimes prescribed for the treatment of angina pectoris.
- The anti-hypertensive drug Clonidine is available in transdermal patch form.
- Transdermal form of the MAOI selegiline, became the first transdermal delivery agent for an antidepressant ^[6].

The objective of this reaserch work was to develop a transdermal system which can produce a constant and prolonged release of the drug, to evaluate the effect of HPMC on the fabrication of the patch and drug release from the patch, to evaluate the effect of plasticizers on the physico-chemical properties of the patch and on drug permeation across the membrane.

MATERIALS AND METHODS

Materials

Amlodipine was kindly supplied as gift samples by Microlabs Pharmaceuticals, Banglore, India. Polymer and plastiziers used were purchased by SD fine chemicals,India. The Drug analysis was performed using UV Spectroscopy. In addition, an electronic balance (Shimadzu AX200), magnetic stirrer (REMI model Mumbai), a sonicator (Spectra Lab, model UCB 40), a hot air oven (Labhosp) and a Franz diffusion cell (self fabrication) were used in this study.

Formulation of transdermal drug delivery system

TDDS was developed using solvent evaporation method. In this polymer is dissolved in particular solvent and then the specified quantity of drug as well as plasticizers were added and was air dried for 24 hrs in petridish with help of inverted funnel for controlled evaporation. A total of 8 formulations were made in as shown in Table 1 [7-9].

Table 1: Formulations Containing HPMC Patches

Drug	Polymers	Plasticizers	Polymer (%)
Amlodipine	НРМС	DBP	1, 1.5, 2, 2.5
		PG	1, 1.5, 2, 2.5

HPMC = hydroxypropyl methyllcellulose PG = Propyleneglycol

DBP = Dibutylphthlate

Preparation of Amlodipine patches

Drug loaded matrix type transdermal films of Amlodipine were prepared by solvent evaporation method. The polymer like HPMC were dissolved in particular solvents with help of magnetic stirrer followed by the addition of drug into the polymeric solution and then the plasticizers were incorporated with continuous stirring and the volume was made up. The resultant solution was casted onto the petridish and an inverted funnel was placed. After 24 hours the films were removed by using sharp knife by inserting along the edge of the films and stored for further studies ^[10].

Evaluation of transdermal patches Physical appearance

All the prepared patches were visually inspected for color, clarity, flexibility and smoothness [11].

Thickness uniformity

The thickness of the formulated film was measured at 3 different points using a calliper and average thickness was calculated ^[12].

Folding endurance

The folding endurance was measured manually for the prepared films. A strip of film 1cm² was cut and repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking or cracking gives the value of folding endurance ^[13].

Percentage moisture absorption

The films were weighed accurately and placed in desiccators containing 100 ml of saturated solution of potassium chloride after 3 days; the films were taken out and weighed. The percentage moisture absorption was calculated using the formula ^{[14].}

% moisture absorption = Final weight – Initial weight x 100

Percentage moisture loss

The films were weighed accurately and placed in a desiccators containing anhydrous calcium chloride. After 3 days, the films were taken out and weighed. The percentage moisture loss was calculated using the formula given below ^[15].

Water vapour transmission rate

Glass vials of 5ml capacity were washed thoroughly and dried to a constant weight in an oven. About 1gm of fused calcium chloride was taken in the vials and the polymer films were fixed over the brim with the help of adhesive tape. Then the vials were weighed and stored in a humidity chamber of 70-80% RH condition for a period of 24 hr. The vials were removed and weighed after 24 hrs to note down the weight gain and transmission rate was found out [16].

Drug content

6.1544 cm² area of the small films was cut and was dissolved in sufficient quantity of methanol. The volume was made up to 100ml. The absorbance of the diluted solution was measured at 238nm and the drug content in the film was calculated ^[17].

In-vitro drug diffusion studies

In- vitro diffusion studies were performed by using Franz diffusion cell with a receptor compartment capacity of 20 ml. The synthetic cellophane membrane was mounted between donor and receptor compartment of the diffusion cell. The formulated patches were cut into size of 1.4 cm radius and placed over the drug release membrane and the receptor compartment of the diffusion cell was filled with phosphate buffer pH 7.4. The whole assembly was fixed on a magnetic stirrer, and the solution in the receptor compartment was constantly and continuously stirred using magnetic beads at 50 rpm. The sample of 2ml were withdrawn at time intervals of 30 min, 1 hr, 1.30 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6hr, 7hr, 8hr and 24 hr and analyzed for drug content spectrophotomerically at 238 nm ^[18-20].

RESULT AND DISCUSSION

Calculation of total drug loading

The formulation of the patch was made in such a way that each small circular patch of 1.4cm radius (which is the radius of the franz diffusion cell) contains 5mg of the drug. The total amount of drug to be loaded in the patch was calculated by measuring the total area of the petri dish in which the patch will be casted. The calculation was done as follows:

Area of the small circular patch = 6.1544 cm^2 Desired drug content in the small patch = 5 mgArea of the petri dish = 67.89 cm^2 Total amount of drug to be loaded = 67.89 x 5 / 6.1544 = 55 mg

Hence 55mg of the drug was added in each formulation in order to get 5mg per small circular patch.

Preparation of transdermal patches

As per the methodology transdermal patches using HPMC were prepared by using solvent casting method. The polymers were dissolved in particular solvent followed by the addition of drug into the polymeric solution. Plasticizers were then added to the drug- polymer solution and were casted on petridish. It was covered by funnel to control evaporation of solvent and allowed to dry at room temperature over night. All the formulations showed a smooth and desirable consistency.

Evaluation of Prepared Transdermal Patches Folding endurance

In general, folding endurance of all the films was found to be satisfactory indicating good strength and elasticity. The observed values are given in Table 2. Folding endurance of HPMC was found to be in the range of 289-300. Folding endurance was found to increase with the polymer content. Dibutyl phthalate showed more endurance than propylene glycol.

Formulations	Folding Endurance	Thickness (mm)	Percentage Moisture loss (%)	Percentage Moisture Absorption (%)	Water Vapour Transmission Rate (gm/cm²/hr)
H1(1% HPMC & PG)	290	0.22	15.38	5.77	0.2981
H2(1.5%HPMC & PG)	293	0.24	13.33	12.05	0.4600
H3(2% HPMC & PG)	294	0.25	5.12	15.64	0.4742
H4(2.5%HPMC & PG)	296	0.26	3.44	20.34	0.4771
H5(1%HPMC & DBP)	294	0.23	12.52	6.61	0.3929
H6(1.5%HPMC&DBP)	296	0.25	9.81	8.63	0.4013
H7(2% HPMC & DBP)	298	0.27	9.65	15.12	0.4471
H8(2.5%HPMC&DBP)	300	0.28	5.88	21.21	0.4471

Table 2: Evaluation of Prepared HPMC Transdermal Patches

(HPMC =hydroxypropyl methyllcellulose ; PG = Propyleneglycol ; DBP = Dibutylphthlate)

 Table 3: Assay and Cumulative drug release of Prepared HPMC Patches

Formulation	Assay (%)	Cumulative drug release at 8 hrs (%)	Cumulative drug release at 24 hrs (%)
H1(1% HPMC & PG)	92.69	92.48	-
H2(1.5%HPMC& PG)	95.83	89.06	_
H3(2% HPMC & PG)	93.61	54.01	91.72
H4(2.5%HPMC& PG)	99.06	48.31	88.52
H5(1%HPMC & DBP)	95.13	93.19	_
H6(1.5%HPMC DBP)	98.14	90.23	_
H7(2%HPMC & DBP)	97.32	60.87	99.07
H8(2.5%HPMC&DBP)	96.74	53.65	89.91

(HPMC =hydroxypropyl methyllcellulose ; PG = Propyleneglycol ; DBP = Dibutylphthlate)

Thickness

Thickness of HPMC were evaluated with the use of a vernier caliper and was found to be in the range of 0.21-0.28 mm as shown in table 2. The thickness was found to be uniform with respect to each formulation and there was an increase of thickness with increase in the percentage of polymer (1%, 1.5%, 2% and 2.5%). The plasticizer type or content does not have any influence on the thickness of the patches.

Percentage moisture loss

Percentage moisture loss for HPMC containing patches was found in the range of 3.44 – 22.22% as shown in table 2. Percentage moisture loss of prepared HPMC patches was found to decrease with increase in the percentage of the polymer (1%, 1.5%,2% and 2.5%) irrespective of the plasticizers (DBP & PG) used, which may be due to the hydrophilic character of both the polymers.

Percentage moisture absorption

Percentage moisture absorption for HPMC was found in the range of 5.21 - 20.34% as shown in

Table 2. The percentage moisture absorption was found to be increased with increase in the polymer content (1%, 1.5%, 2%, 2.5%) irrespective of plasticizers (DBP & PG) used. This may be due to the hydrophilic character of polymers which readily absorbs water.

Water vapour transmission rate

Water vapour transmission rates for HPMC were found in the range of 0.2981 – 0.4986gm/cm²/hr as shown in table 2. Water vapour transmission rate results were found to be similar to the results obtained in moisture absorption studies.

Drug content

Drug content in each small circular patches were analyzed spectrophotmetrically and It was observed that all the formulations showed a satisfactory drug content values ranging from 92 – 99% as given in Table 2 which is in accordance with the standard values prescribed for drug content analysis.



Figure 1: Diffusion study of formulations H1, H2, H3 and H4



Figure 2: Diffusion study of formulations H5,H6, H7 and H8

Diffusion study

Effect of HPMC patches on drug release

As shown in Table 3, the drug release rate among the HPMC patches was found to be decreased when concentration of HPMC was increased. This may be due to increased swelling of the polymer when concentration is increased which leads to increased viscosity of the medium and thus increases the mean diffusional path length of the drug molecule to get released into the diffusion medium. The cumulative drug release was found to be around 90% for patches with 1 and 1.5% of HPMC and around 50-60% at 8 hours for patches with 2% and 2.5 % of HPMC. Since almost complete release was obtained with 1% and 1.5% HPMC within 8 hours they are not considered for further studies. Similarly patches with 2.5% HPMC could not provide a complete release at 24 hours and hence they were also not selected. Formulations H3 & H7 which have 2 % HPMC were found to be satisfactory as they produced a sustained as well as complete release for 24 hours. Among these 2 formulations, formulation H7 which contains DBP as plasticizers was chosen as the best formulation in comparison to H3, which contains PG as plasticizers because H7 gave almost 100 % release at 24 hours whereas H3 give 91.72% release respectively.

CONCLUSION

Delivery of drug into systemic circulation through skin has created lot of interest among pharmaceutical scientist during recent years. The transdermal system offers several advantages over oral dosage forms which include avoidance of hepatic first pass effect metabolism, decrease in frequency of administration, providing steady state plasma concentration and improves patient compliance etc. Hence in this study an attempt was made to deliver Amlodipine transdermally in order to provide a constant serum level of drug over the prolonged period of time. Polymers like chitosan were selected for the study and were used at different concentrations. PG and DBP were incorporated as plasticizers in the formulations. On evaluation of various parameters it was found that the polymers produced satisfactory results with respect to the physical characteristics of the film and the synthetic release characteristics across membrane. The release profile suggested that increase in polymer content led to decrease in release rate of the drug. Lower concentration of polymers gave an initial burst release of about 50% within 2 hours and as concentration were increased they were able to sustained the release for prolonged period but could not release the entire content in the prescribed time limit. Hence it was concluded that concentration of 2% HPMC with DBP (H7) as plasticizers will be the most suitable one for the transdermal systems of Amlodipine as it showed sustained and complete release at a period of 24 hours. Further studies using various animal models can throw more light on the variability of the prepared transdermal systems.

ACKNOWLEDGEMENT

First and foremost it gives me great pleasure to record my deep sense of gratitude and indebtedness to my esteemed guide Dr.N.Arunkumar M.Pharm.,PhD., Asst Professor, Department of Pharmaceutics, KMCH College of Pharmacy, for his constant insight, guidance, countless serenity, encouragement and pain taking efforts in my project work . I am indebted to his kindness and never failing co-operation. With immense pleasure I express my deep gratitude to computer lab technicians, library staff and other lab technicians of KMCH College of Pharmacy, and all those who helped directly and indirectly in every aspect of constructing this work. I express my sincere thanks to Sandra Joji Samuel who supported me throughout my project and helped me whenever I required.

REFERENCES

- [1] Bhowmik D, Chiranjib, Margret C, Jayakar B, Sampath K P. Recent Advances in Transdermal Drug Delivery System: Int. J. Pharm. Tech. Res. 2010 jan; 2(1): 68-77.
- [2] Arunachalam A, Karthikeyan M, Vinay K, Prathap M, Ashutoshkumar S. Transdermal drug delivery system a review: Curr. Pharm. res. 2010 Oct- Dec; 1 (1): 70-72.
- [3] Gaur P, Mishra S, Purohit S, Dave K. Transdermal drug delivery system a review: Asian. J. pharm. Clin. res. 2009 Jan - Mar; 2 (1): 14-19.
- [4] Ashok K, Nikhila P, Lakshmana S, Gopal V. Transdermal drug delivery system an overview: Int. J. pharm. Sci. rev. res. 2010 July- August; 3(2): 49-52.
- [5] Hadgraft J, Guy R. H. Transdermal Drug Delivery.2nd ed. New York: Marcel Dekker, 35. p.14-16.
- [6] Jain.N.K, Controlled and novel drug delivery: Transdermal drug delivery system novel method New Delhi: CBS publishers and distributors; 1997. P.428-430.
- [7] Hemangi .J, Jitendra S, Desai .B, Keyur.D. Design and evaluation of Amlodipine besilate transdermal patches containing film former: ijprd. 2009 sept; 7(001): 1-12.
- [8] Jadhav.R.T, Gattani S.G, Surana S.J. Formulation and evaluation of transdermal films of diclofenac sodium: Int. J. pharm. Tech. res. 2009 oct-dec; 1(4): 1508-1511.
- [9] Pravin G, Atul.G, Radhika P.R, Sivakumar.T. Design and evaluation of hydroxypropyl methylcellulose(HPMC) based polymeric film of enalprilat maleate: Int. J. pharm. Tech. res. 2010 Jan- Mar; 2(1): 274-280.
- [10] Mangesh R, Design and evaluation of transdermal films of lornoxicam: Int. J. pharm. biosci. 2011Apr- Jun; 2(2): 54-60.
- [11] Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV, Kakade RS, et al., Preparation of transdermal monolithic systems of

indapamide by solvent casting method and the use of vegetable oils as permeation enhancer: Int. J. Green Pharm. 2(2): 129-33.

- [12] Murthy TEGK, Kishore VS, Effect of casting solvent on permeability of antihypertensive drugs through ethyl cellulose films: J. Sci. Indian Res. 2008 feb; 67(2): 147-150.
- [13] .Murthy TEGK and Kishore VS, Effect of casting solvent and polymer on permeability of propranolol hydrochloride through membrane controlled transdermal drug delivery system: Indian J. Pharm. Sci. 2007sept; 69(5): 646-650.
- [14] Subramanian K, Sathyapriya LS, Jayaprakash S, Prabhu RS, Abirami A, Madhumitha B et al. An Approach to the formulation and evaluation of transdermal DDS of isoxsuprine HCl: Int. J. Pharm. Sci. Tech. 2008; 1(1): 8 22.
- [15] Shinde AJ, Garala KC, More HN, Development and characterization of transdermal therapeutics system of tramadol hydrochloride: Asian J. Pharm. 2008 Mar; 2(4): 265-269.
- [16] Pandit V, Khanum A, Bhaskaran S, Banu V, Formulation and evaluation of transdermal films for the treatment of overactive bladder: Int. J. Pharm. Tech. Res. 2009July-Sept; 1(3): 799-804.
- [17] Rao V, Mamatha T, Mukkanti K and Ramesh. Transdermal drug delivery system for atomoxetine hydrochloride- in vitro and ex vivo evaluation: Curr. Trends Biotech. Pharm. 2009 July; 3(2): 96 - 188.
- [18] Satturwar PM, Fulzele SV, Dorle AK, Evaluation of polymerized rosin for the formulation and development of transdermal drug delivery system: A Technical Note: AAPS Pharm. Sci. Tech. 2005 Dec; 6(4): 649 - 654.
- [19] R. K. Kar, S.Mohapatra, B.B.Barik .Design and Characterization of Controlled Release Matrix Tablets of Lamivudine: Asian J. Pharm. Clin. Res. 2009; 2(2): 212-220.
- [20] Joseph S D. Transdermal Patches: An Innovative Drug Delivery System That Has Raised Serious Safety Concerns. NewsInferno. [internet]. 2006 [cited 2011 feb 22]. Availaible from: URL: http://www.newsinferno.com